Market Cap 189.72M
Revenue (ttm) 40.37M
Net Income (ttm) -119.72M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -296.56%
Debt to Equity Ratio 0.00
Volume 1,235,600
Avg Vol 676,992
Day's Range N/A - N/A
Shares Out 60.42M
Stochastic %K 29%
Beta 1.27
Analysts Strong Sell
Price Target $15.38

Company Profile

Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease. The company also provides research program for the treatment of Huntington's disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neu...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 259 5340
Address:
75 Hayden Avenue, Lexington, United States
somewon
somewon Jul. 23 at 2:51 PM
$VYGR this is trading essentially at cash value. Good phase 1/2 trial results later this year and this will either pop or be a cheap buyout for a big company
0 · Reply
buffalochips62
buffalochips62 Jul. 22 at 2:14 PM
$VYGR whos NOT adding at these levels, and why not ?
0 · Reply
HarperLucky
HarperLucky Jul. 21 at 10:30 PM
$VYGR Has a partnerships involving its capsid technology with major pharmaceutical companies, including programs connected to Novartis, Alexion/AstraZeneca Rare Disease and Neurocrine. These collaborations validate outside interest in its technology platform.
0 · Reply
StockScanners
StockScanners Jul. 18 at 8:32 AM
$VYGR keep watch if this holds above 3.10
0 · Reply
notreload_ai
notreload_ai Jul. 14 at 2:57 PM
$BIIB diranersen showed robust tau reductions (50-65%) and slowed cognitive decline by up to 26% in its Phase 2 CELIA trial. Despite missing the primary endpoint, the drug advances to Phase 3 in 2027 with a favorable safety profile. Mixed Phase 2 results still advance the competitive tau gene-silencing space including $VYGR, $ARWR, and $DNLI. https://notreload.xyz/xy/biogen-diranersen-phase-2-results-promising-tau-drug-misses-primary-endpoint/
1 · Reply
LibertarianTreehugger
LibertarianTreehugger Jul. 14 at 1:49 AM
Voyager's Alzheimer's Therapy Could Open a New Front in Treatment: https://jlsfund.substack.com/p/voyagers-alzheimers-therapy-could $VYGR
0 · Reply
tumanako
tumanako Jul. 4 at 5:32 AM
$VYGR A Spread Triple Top is a classic Point and Figure (P&F) chart pattern defined by at least three resistance peaks separated by broader, non-adjacent retracements. A breakout occurs when the price punches through that ceiling, projecting a significant bullish move equal to the pattern's width multiplied by the box size
2 · Reply
tumanako
tumanako Jul. 2 at 1:40 AM
$VYGR Shall have good news soon. It is a sleeper now.
0 · Reply
focafoca99
focafoca99 Jun. 29 at 12:13 PM
$VYGR presenting its tau-targeted gene therapy VY1706 at AAIC 2026 poster session.
0 · Reply
Reacting_
Reacting_ Jun. 14 at 10:10 AM
0 · Reply
Latest News on VYGR
Voyager Therapeutics Transcript: AGM 2026

Jun 9, 2026, 9:00 AM EDT - 6 weeks ago

Voyager Therapeutics Transcript: AGM 2026


Voyager Therapeutics Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 2 months ago

Voyager Therapeutics Quarterly report: Q1 2026


Voyager Therapeutics Earnings release: Q1 2026

May 7, 2026, 7:00 AM EDT - 2 months ago

Voyager Therapeutics Earnings release: Q1 2026


Voyager Therapeutics Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 3 months ago

Voyager Therapeutics Proxy statement: Proxy filing


Voyager Therapeutics Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 3 months ago

Voyager Therapeutics Proxy statement: Proxy filing


Voyager Therapeutics Proxy statement: Proxy filing

Apr 10, 2026, 8:00 AM EDT - 3 months ago

Voyager Therapeutics Proxy statement: Proxy filing


Voyager Therapeutics Transcript: Stifel 2026 Virtual CNS Forum

Mar 18, 2026, 12:30 PM EDT - 4 months ago

Voyager Therapeutics Transcript: Stifel 2026 Virtual CNS Forum


Voyager Therapeutics Earnings release: Q4 2025

Mar 9, 2026, 7:00 AM EDT - 4 months ago

Voyager Therapeutics Earnings release: Q4 2025


Voyager Therapeutics Annual report: Q4 2025

Mar 9, 2026, 7:00 AM EDT - 4 months ago

Voyager Therapeutics Annual report: Q4 2025


Voyager to Present at Upcoming Investor Conferences

Feb 9, 2026, 8:00 AM EST - 5 months ago

Voyager to Present at Upcoming Investor Conferences


Voyager Therapeutics Earnings release: Q3 2025

Nov 10, 2025, 8:00 AM EST - 9 months ago

Voyager Therapeutics Earnings release: Q3 2025


Voyager Therapeutics Quarterly report: Q3 2025

Nov 10, 2025, 8:00 AM EST - 9 months ago

Voyager Therapeutics Quarterly report: Q3 2025


Voyager Therapeutics Registration statement: Registration Filing

Nov 10, 2025, 7:00 AM EST - 9 months ago

Voyager Therapeutics Registration statement: Registration Filing


Voyager Therapeutics Quarterly report: Q2 2025

Aug 6, 2025, 4:00 PM EDT - 1 year ago

Voyager Therapeutics Quarterly report: Q2 2025


Voyager Therapeutics Earnings release: Q2 2025

Aug 6, 2025, 4:00 PM EDT - 1 year ago

Voyager Therapeutics Earnings release: Q2 2025


Voyager Therapeutics Quarterly report: Q1 2025

May 6, 2025, 4:00 PM EDT - 1 year ago

Voyager Therapeutics Quarterly report: Q1 2025


Voyager Therapeutics Earnings release: Q1 2025

May 6, 2025, 4:00 PM EDT - 1 year ago

Voyager Therapeutics Earnings release: Q1 2025


Voyager Therapeutics Proxy statement: Proxy Filing

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Voyager Therapeutics Proxy statement: Proxy Filing


Voyager Therapeutics Proxy statement: Proxy Filing

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Voyager Therapeutics Proxy statement: Proxy Filing


Voyager Therapeutics Transcript: Virtual CNS Forum

Mar 19, 2025, 11:00 AM EDT - 1 year ago

Voyager Therapeutics Transcript: Virtual CNS Forum


Voyager Therapeutics Earnings Call Transcript: Q4 2024

Mar 11, 2025, 4:30 PM EDT - 1 year ago

Voyager Therapeutics Earnings Call Transcript: Q4 2024


Voyager Therapeutics Annual report: Q4 2024

Mar 11, 2025, 4:30 PM EDT - 1 year ago

Voyager Therapeutics Annual report: Q4 2024


Voyager Therapeutics Earnings release: Q4 2024

Mar 11, 2025, 4:30 PM EDT - 1 year ago

Voyager Therapeutics Earnings release: Q4 2024


Voyager Provides Update on SOD1 ALS Gene Therapy Program

Feb 11, 2025, 7:00 AM EST - 1 year ago

Voyager Provides Update on SOD1 ALS Gene Therapy Program


Voyager Therapeutics Earnings Call Transcript: Q3 2024

Nov 12, 2024, 4:30 PM EST - 1 year ago

Voyager Therapeutics Earnings Call Transcript: Q3 2024


Voyager Therapeutics Quarterly report: Q3 2024

Nov 12, 2024, 4:30 PM EST - 1 year ago

Voyager Therapeutics Quarterly report: Q3 2024


Voyager Therapeutics Earnings release: Q3 2024

Nov 12, 2024, 4:30 PM EST - 1 year ago

Voyager Therapeutics Earnings release: Q3 2024


Voyager Therapeutics Earnings Call Transcript: Q2 2024

Aug 6, 2024, 4:30 PM EDT - 2 years ago

Voyager Therapeutics Earnings Call Transcript: Q2 2024


Voyager Therapeutics Quarterly report: Q2 2024

Aug 6, 2024, 4:30 PM EDT - 2 years ago

Voyager Therapeutics Quarterly report: Q2 2024


Voyager Therapeutics Earnings release: Q2 2024

Aug 6, 2024, 4:30 PM EDT - 2 years ago

Voyager Therapeutics Earnings release: Q2 2024


Voyager Therapeutics Earnings Call Transcript: Q1 2024

May 13, 2024, 4:30 PM EDT - 2 years ago

Voyager Therapeutics Earnings Call Transcript: Q1 2024


Voyager Therapeutics Quarterly report: Q1 2024

May 13, 2024, 4:30 PM EDT - 2 years ago

Voyager Therapeutics Quarterly report: Q1 2024


Voyager Therapeutics Earnings release: Q1 2024

May 13, 2024, 4:30 PM EDT - 2 years ago

Voyager Therapeutics Earnings release: Q1 2024


somewon
somewon Jul. 23 at 2:51 PM
$VYGR this is trading essentially at cash value. Good phase 1/2 trial results later this year and this will either pop or be a cheap buyout for a big company
0 · Reply
buffalochips62
buffalochips62 Jul. 22 at 2:14 PM
$VYGR whos NOT adding at these levels, and why not ?
0 · Reply
HarperLucky
HarperLucky Jul. 21 at 10:30 PM
$VYGR Has a partnerships involving its capsid technology with major pharmaceutical companies, including programs connected to Novartis, Alexion/AstraZeneca Rare Disease and Neurocrine. These collaborations validate outside interest in its technology platform.
0 · Reply
StockScanners
StockScanners Jul. 18 at 8:32 AM
$VYGR keep watch if this holds above 3.10
0 · Reply
notreload_ai
notreload_ai Jul. 14 at 2:57 PM
$BIIB diranersen showed robust tau reductions (50-65%) and slowed cognitive decline by up to 26% in its Phase 2 CELIA trial. Despite missing the primary endpoint, the drug advances to Phase 3 in 2027 with a favorable safety profile. Mixed Phase 2 results still advance the competitive tau gene-silencing space including $VYGR, $ARWR, and $DNLI. https://notreload.xyz/xy/biogen-diranersen-phase-2-results-promising-tau-drug-misses-primary-endpoint/
1 · Reply
LibertarianTreehugger
LibertarianTreehugger Jul. 14 at 1:49 AM
Voyager's Alzheimer's Therapy Could Open a New Front in Treatment: https://jlsfund.substack.com/p/voyagers-alzheimers-therapy-could $VYGR
0 · Reply
tumanako
tumanako Jul. 4 at 5:32 AM
$VYGR A Spread Triple Top is a classic Point and Figure (P&F) chart pattern defined by at least three resistance peaks separated by broader, non-adjacent retracements. A breakout occurs when the price punches through that ceiling, projecting a significant bullish move equal to the pattern's width multiplied by the box size
2 · Reply
tumanako
tumanako Jul. 2 at 1:40 AM
$VYGR Shall have good news soon. It is a sleeper now.
0 · Reply
focafoca99
focafoca99 Jun. 29 at 12:13 PM
$VYGR presenting its tau-targeted gene therapy VY1706 at AAIC 2026 poster session.
0 · Reply
Reacting_
Reacting_ Jun. 14 at 10:10 AM
0 · Reply
tumanako
tumanako Jun. 13 at 6:51 AM
$VYGR The price action is quite weak, but the on balance volume is quite healthy. What do all of you think?
0 · Reply
Orlandotrader
Orlandotrader Jun. 12 at 8:35 PM
$VYGR Better start this phase 1 Tau Trial!!
1 · Reply
focafoca99
focafoca99 Jun. 10 at 8:32 PM
$VYGR increased its authorized common shares to 240 million, up from 120 million, after stockholder approval at its 2026 annual meeting.
0 · Reply
SuperGreenToday
SuperGreenToday Jun. 5 at 10:57 AM
$VYGR Share Price: $3.63 Contract Selected: Jan 15, 2027 $4.0 Calls Buy Zone: $1.13 – $1.40 Target Zone: $1.81 – $2.22 Potential Upside: 51% ROI Time to Expiration: 223 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
biotech
biotech Jun. 3 at 10:36 AM
BARRONS calling out $SGMO getting Alzheimer’s Drugs Into the Brain Is Hard. Now There’s a New Trick. To get gene therapies into cells both $VYGR and $SGMO are developing capsids that first open blood-brain portals, then deliver genetic cargoes to brain cells Sangamo is developing gene therapies in collaborations with $LLY Lilly, Astrellas (they mean Astellas) , and Roche. $RHHBY https://www.barrons.com/articles/alzheimers-drugs-brain-biotech-a26d24d8
0 · Reply
DARKP00L
DARKP00L Jun. 1 at 1:57 PM
$VYGR 08:02 on Jun. 01 2026 Voyager Therapeutics Issued FDA Clearance For Its Investigational New Drug Application For VY1706 To Treat Alzheimer's Disease #tradeideas
0 · Reply
Stock_Catcher
Stock_Catcher Jun. 1 at 12:01 PM
$VYGR Voyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer’s Disease
0 · Reply
Orlandotrader
Orlandotrader May. 27 at 4:42 PM
$VYGR Ahh the Summer of TAU is upon us!!
0 · Reply
NVDAMillionaire
NVDAMillionaire May. 20 at 8:33 PM
$VYGR Great piece that accurately captures VYGR's current position. So if you want to refresh your understanding of VYGR or learn about VYGR for the first time, this is essential reading. https://everyticker.com/quote/VYGR/analysis/voyager-s-6-8-billion-platform-gamble-why-2026-data-will-define-the-gene-therapy-upstart-nasdaq-vygr
0 · Reply
Orlandotrader
Orlandotrader May. 18 at 8:28 PM
$VYGR Shit day. Adding at 3$
0 · Reply
Orlandotrader
Orlandotrader May. 15 at 1:47 AM
$VYGR It’s gonna Run my friends
0 · Reply
0fabiocoppola
0fabiocoppola May. 14 at 11:54 AM
$VYGR what's happening?
2 · Reply